Display options
Cite
Stanger BZ. Quit your YAPing: a new target for cancer therapy. Genes Dev. 2012;26(12):1263-7doi: 10.1101/gad.196501.112.
Stanger, B. Z. (2012). Quit your YAPing: a new target for cancer therapy. Genes & development, 26(12), 1263-7. https://doi.org/10.1101/gad.196501.112
Stanger, Ben Z. "Quit your YAPing: a new target for cancer therapy." Genes & development vol. 26,12 (2012): 1263-7. doi: https://doi.org/10.1101/gad.196501.112
Stanger BZ. Quit your YAPing: a new target for cancer therapy. Genes Dev. 2012 Jun 15;26(12):1263-7. doi: 10.1101/gad.196501.112. PMID: 22713867; PMCID: PMC3387654.
Copy Download .nbib Format: NLM
Share it on

Genes Dev. 2012 Jun 15;26(12):1263-7. doi: 10.1101/gad.196501.112.

Quit your YAPing: a new target for cancer therapy.

Genes & development

Ben Z Stanger

Affiliations

  1. Gastroenterology Division, Department of Medicine, Department of Cell and Developmental Biology, Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA. [email protected]

PMID: 22713867 PMCID: PMC3387654 DOI: 10.1101/gad.196501.112

Abstract

The Hippo pathway is an evolutionarily conserved signaling module that plays multiple roles in embryonic development. Components of the pathway, which includes a kinase cascade and a downstream complex composed of YAP and TEAD transcription factors, are dysregulated in a significant fraction of human cancers. In this issue of Genes & Development, Liu-Chittenden and colleagues (pp. 1300-1305) use genetic and pharmacological means to disrupt the active YAP-TEAD complex. As this intervention impedes tumorigenesis in the liver with no apparent effect on normal liver homeostasis, the work paves the way for the development of new strategies to target this pervasive oncogenic pathway.

References

  1. Cancer Res. 2005 Sep 1;65(17):7561-7 - PubMed
  2. Oncogene. 2005 Jun 16;24(26):4232-42 - PubMed
  3. Dev Cell. 2010 Oct 19;19(4):491-505 - PubMed
  4. Development. 1995 Apr;121(4):1053-63 - PubMed
  5. Proc Natl Acad Sci U S A. 1986 Dec;83(23):9129-33 - PubMed
  6. Development. 2011 Jan;138(1):9-22 - PubMed
  7. Genes Dev. 2010 May;24(9):862-74 - PubMed
  8. Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12405-10 - PubMed
  9. Cancer Res. 2008 Apr 15;68(8):2592-8 - PubMed
  10. Lancet. 2009 Jun 6;373(9679):1974-86 - PubMed
  11. Nature. 2011 Aug 03;478(7370):524-8 - PubMed
  12. Genes Dev. 2007 Nov 1;21(21):2747-61 - PubMed
  13. Semin Ophthalmol. 2001 Dec;16(4):201-6 - PubMed
  14. Genes Dev. 2009 Dec 1;23(23):2729-41 - PubMed
  15. Mol Cell Biol. 2008 Apr;28(7):2426-36 - PubMed
  16. Genes Dev. 2012 Jun 15;26(12):1300-5 - PubMed
  17. J Cell Physiol. 2011 Apr;226(4):928-39 - PubMed
  18. Curr Biol. 2007 Dec 4;17(23):2054-60 - PubMed
  19. Cell. 2006 Jun 30;125(7):1253-67 - PubMed
  20. Dev Cell. 2010 Jul 20;19(1):27-38 - PubMed
  21. Mol Cell Biol. 2008 May;28(10):3177-89 - PubMed
  22. Genes Dev. 1995 Mar 1;9(5):534-46 - PubMed
  23. Cell. 2007 Sep 21;130(6):1120-33 - PubMed
  24. Genes Dev. 2010 Jan 1;24(1):72-85 - PubMed
  25. Genes Dev. 2010 Nov 1;24(21):2383-8 - PubMed
  26. J Clin Oncol. 2006 Nov 20;24(33):5223-33 - PubMed
  27. Nat Chem Biol. 2012 Jan 29;8(3):277-84 - PubMed

Publication Types